In addition, our results might also explain the fall in ACPA levels resulting from the dual blockade of TNFα and LTα with etanercept [59], and the blockade of TNFα by infliximab [11] in patients with RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.